Related Experiment Video
Updated: Jun 17, 2026
The Muscle Cuff Regenerative Peripheral Nerve Interface for the Amplification of Intact Peripheral Nerve Signals
Published on: January 13, 2022
Ca2+ sensitizers: An emerging class of agents for counterbalancing weakness in skeletal muscle diseases?
1Department of Clinical Neurophysiology, Uppsala University Hospital, Sweden. julien.ochala@neurofys.uu.se
Abstract:
Ca(2+) ions are key regulators of skeletal muscle contraction. By binding to contractile proteins, they initiate a cascade of molecular events leading to cross-bridge formation and ultimately, muscle shortening and force production. The ability of contractile proteins to respond to Ca(2+) attachment, also known as Ca(2+) sensitivity, is often compromised in acquired and congenital skeletal muscle disorders. It constitutes, undoubtedly, a major physiological cause of weakness for patients. In this review, we discuss recent studies giving strong molecular and cellular evidence that pharmacological modulators of some of the contractile proteins, also termed Ca(2+) sensitizers, are efficient agents to improve Ca(2+) sensitivity and function in diseased skeletal muscle cells. In fact, they compensate for the impaired contractile proteins response to Ca(2+) binding. Currently, such Ca(2+) sensitizing compounds are successfully used for reducing problems in cardiac disorders. Therefore, in the future, under certain conditions, these agents may represent an emerging class of agents to enhance the quality of life of patients suffering from skeletal muscle weakness.
Insights
Pharmacological calcium (Ca2+) sensitizers can improve muscle function in skeletal muscle disorders by enhancing the response of contractile proteins to calcium. These compounds may offer future therapeutic benefits for patients with muscle weakness.
Area of Science:
- Biochemistry
- Physiology
- Pharmacology
Background:
- Calcium ions (Ca2+) are critical for skeletal muscle contraction by regulating contractile proteins.
- Impaired Ca2+ sensitivity of contractile proteins is a primary cause of muscle weakness in various disorders.
- Current treatments for skeletal muscle weakness are limited.
Purpose of the Study:
- To review recent evidence on pharmacological Ca2+ sensitizers for treating skeletal muscle disorders.
- To explore the potential of Ca2+ sensitizers as a therapeutic strategy for muscle weakness.
Main Methods:
- Review of recent molecular and cellular studies.
- Analysis of pharmacological modulators of contractile proteins.
- Examination of Ca2+ sensitizing compounds in cardiac and skeletal muscle.
Main Results:
- Ca2+ sensitizers demonstrate efficacy in improving Ca2+ sensitivity and function in diseased skeletal muscle cells.
- These agents compensate for impaired contractile protein response to Ca2+ binding.
- Ca2+ sensitizing compounds are already successfully used in cardiac disorders.
Conclusions:
- Pharmacological Ca2+ sensitizers represent a promising therapeutic approach for skeletal muscle weakness.
- These agents could enhance the quality of life for patients with muscle disorders.
- Further research may establish Ca2+ sensitizers as a key treatment modality under specific conditions.
Related Concept Videos
01:28Classification of Skeletal Muscle Relaxants
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
01:29Spasmolytic Agents: Chemical Classification
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also promote...
01:21Skeletal Muscle Relaxants: Adverse Effects
Unlike...
01:31Skeletal Muscle Relaxants: Therapeutic Uses
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
01:24Centrally Acting Muscle Relaxants: Therapeutic Uses
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...